INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA

Alexander Schonfeld, Amihai Schattner, Madeleine Crespi, Hanoch Levavi, Jacob Shoham, Schmuel Nitke, David Wallach, Talia Hahn, Ovadia Yarden, Thomas Doerner, Michet Revel

Research output: Contribution to journalArticlepeer-review

135 Scopus citations

Abstract

A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×106 units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.

Original languageEnglish
Pages (from-to)1038-1042
Number of pages5
JournalThe Lancet
Volume323
Issue number8385
DOIs
StatePublished - 12 May 1984
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by InterYeda Ltd, Israel.

Fingerprint

Dive into the research topics of 'INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA'. Together they form a unique fingerprint.

Cite this